|
|
|
v | |
| Foreword |
|
ix | |
|
|
| Preface |
|
xi | |
| Color Plates |
|
xiii | |
|
Section I Basic concepts of atherothrombosis |
|
|
1 | (186) |
|
Fundamentals of the thrombosis cascade: interaction between platelets and the coagulation cascade |
|
|
3 | (8) |
|
|
|
|
|
|
|
Platelet receptors and their role in atherothrombosis |
|
|
11 | (8) |
|
|
|
|
|
Laboratory assessment of platelet function and coagulation |
|
|
19 | (16) |
|
|
|
|
|
|
|
Section II Antithrombotic drugs |
|
|
|
|
|
33 | (2) |
|
Cyclooxygenase inhibition in atherothrombotic disease |
|
|
35 | (10) |
|
|
|
|
|
|
|
P2Y12 receptor antagonism: from bench to bedside |
|
|
45 | (8) |
|
|
|
|
|
Timing, dosing and length of clopidogrel therapy |
|
|
53 | (8) |
|
|
|
|
|
Resistance to antiplatelet drugs: aspirin |
|
|
61 | (6) |
|
|
|
|
|
Resistance to antiplatelet drugs: clopidogrel |
|
|
67 | (12) |
|
|
|
|
|
|
|
Prasugrel -- a third-generation thienopyridine |
|
|
79 | (6) |
|
|
|
|
|
Direct oral P2Y12 inhibition: AZD6140 (Ticagrelor) |
|
|
85 | (6) |
|
|
|
|
|
Emerging oral antiplatelet receptor inhibitors |
|
|
91 | (10) |
|
|
|
|
|
|
|
Intravenous antiplatelet drugs |
|
|
99 | (2) |
|
Platelet glycoprotein IIb/IIIa receptor antagonists: fundamental and pharmacological aspects |
|
|
101 | (6) |
|
|
|
|
|
Platelet glycoprotein IIb/IIIa receptor antagonists: a guide to patient selection and optimal use |
|
|
107 | (8) |
|
|
|
|
|
|
|
|
|
115 | (12) |
|
|
|
|
|
Thrombin inhibitors and thrombin generation inhibitors |
|
|
125 | (2) |
|
Indirect thrombin inhibitors: fundamentals and guide to optimal therapy using unfractionated heparin and low-molecular-weight heparins |
|
|
127 | (8) |
|
|
|
|
|
Direct thrombin inhibitors |
|
|
135 | (10) |
|
|
|
|
|
|
|
Fondaparinux in acute coronary syndromes |
|
|
145 | (8) |
|
|
|
|
|
153 | (10) |
|
|
|
|
|
|
|
|
|
161 | (2) |
|
Fibrinolytics: current indications and treatment modalities in the absence of mechanical reperfusion |
|
|
163 | (14) |
|
|
|
|
|
Fibrinolytics and percutaneous coronary intervention |
|
|
177 | (10) |
|
|
|
Francisco Fernandez-Aviles |
|
|
Section III Special situations |
|
|
187 | (76) |
|
Role of facilitated percutaneous coronary intervention in ST-elevation myocardial infarction |
|
|
189 | (8) |
|
|
|
|
|
Antithrombotic treatment in vein graft interventions |
|
|
197 | (8) |
|
|
|
|
|
Antiplatelet therapy in diabetes mellitus |
|
|
205 | (6) |
|
|
|
|
|
|
|
Stent thrombosis in the era of drug-eluting stents |
|
|
211 | (10) |
|
|
|
|
|
|
|
Bleeding complications: anticoagulant and antiplatelet therapy control |
|
|
221 | (8) |
|
|
|
|
|
Heparin-induced thrombocytopenia: etiopathogenesis, clinical presentation, and management |
|
|
229 | (12) |
|
|
|
Antithrombotic therapies for patients with cerebrovascular, peripheral arterial, and coronary artery disease |
|
|
241 | (10) |
|
|
|
|
|
Dual antiplatelet strategies in patients requiring vitamin K antagonists |
|
|
251 | (12) |
|
|
|
|
|
|
| Appendix |
|
263 | (8) |
|
|
|
|
| Index |
|
271 | |
Daugiau apie elektronines knygas